BSEBoard Meeting5d ago · 5 Nov 2026, 04:49 pm
In compliance with Regulation 30 read with Schedule III, Regulation 33 and other applicable provisions of the SEBI Listing Regulations, the Board of Directors of Gujarat Terce Laboratories Limited ('the Company'), at their Meeting held today viz. Thursday, 5 November 2026, has inter-alia, approved Unaudited Standalone Financial Results of the Company for the second quarter and half year ended 30 September 2026, subjected to Limited Review of the Statutory Auditor of the Company.
Gujarat Terce Laboratories Ltd · 524314
✦ AI SummaryResults
Gujarat Terce Laboratories Ltd has approved its unaudited standalone financial results for the second quarter and half year ended 30 September 2026, subject to a limited review by its statutory auditor. The results are available on the company's website.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Gujarat Terce Laboratories Ltd - 524314 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 5 November 2026 - Unaudited Standalone Financial Results Of The Company For The Second Quarter And Half Year Ended 30 September 2026
Attachments (1)
📄pdf
Download →
a575216b-0bb2-47be-aacd-34f3d437e6ec.pdf
View document text
5 November 2026
BSE Limited
(Security Code: 524314)
Phiroze Jeejeeboy Towers,
Dalal Street, Fort,
Mumbai- 400 001.
Dear Sirs,
Sub: Outcome of the Board Meeting held on 5 November 2026 – Unaudited Standalone Financial Results of the Company
for the second quarter and half year ended 30 September 2026 - Regulations 30 and 33 of the Securities and Exchange
Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)
Ref: Intimation of Board Meeting vide letter dated 29 October 2026
We hereby inform you that, in compliance with Regulation 30 read with Schedule III, Regulation 33 and other applicable
provisions of the SEBI Listing Regulations, the Board of Directors of Gujarat Terce Laboratories Limited (“the Company”), at
their Meeting held today viz. Thursday, 5 November 2026, has inter-alia, approved Unaudited Standalone Financial Results
of the Company for the second quarter and half year ended 30 September 2026, subjected to Limited Review of the Statutory
Auditor of the Company.
In this regard, please find enclosed the following documents prepared in compliance with Regulations 33 and 47 (as
applicable) of the SEBI Listing Regulations:
1. Unaudited Standalone Financial Results for the second quarter and half year ended 30 September 2026, and notes
thereon;
2. Unmodified Limited Review Report on the Unaudited Standalone Financial Results for the second quarter and half
year ended 30 September 2026, issued by the Company’s Statutory Auditor – Shah Doshi Patel & Associates LLP;
The Meeting of the Board of Directors of the Company commenced at 3:00 p.m. (IST) and concluded at 4:35 p.m. (IST).
This intimation is also being uploaded on the website of the Company and can be accessed at the weblink:
https://www.gujaratterce.in/financial-results/
Thanking you
For Gujarat Terce Laboratories Limited
Ms. Ashka Solanki
Company Secretary
Enclosures: As above